<DOC>
	<DOCNO>NCT00580801</DOCNO>
	<brief_summary>The purpose study evaluate activity safety telaprevir Hepatitis C Virus ( HCV ) Genotype 4 , alone combination standard therapy , , pegylated-interferon-alfa-2a ribavirin treatment-naive ( never treat antiretroviral therapy ) participant .</brief_summary>
	<brief_title>An Exploratory Study Telaprevir Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection</brief_title>
	<detailed_description>This Phase 2a , partially-blind , randomize ( study drug assign chance ) multiple-dose study evaluate activity safety telaprevir HCV early viral kinetics treatment-naive participant chronically infect HCV Genotype 4 . The study consist 4 part : Screening period ( 6-week ) ; Investigational Treatment period ( consist 2-week treatment telaprevir telaprevir+standard treatment placebo ) ; Standard Treatment period ( consist 46 48-week standard treatment ) ; Follow-up period ( 24-week ) . The activity telaprevir evaluate early viral kinetic parameter along viral response pharmacokinetic assessment investigational treatment phase . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participant chronic Genotype 4 Hepatitis C infection Plasma hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) level great 10,000 International unit per milliliter ( IU/mL ) Screening Participant never receive treatment HCV Participant good health ( besides HCV infection ) , opinion Investigator , judge basis medical history physical examination ( include vital sign screen electrocardiogram [ ECG ] ) , chronic medical condition stable medical control Participant willing refrain concomitant use medication substance Participants history evidence cirrhosis history suspicion alcohol , barbiturate , amphetamine recreational narcotic drug use , Investigator 's opinion would compromise participant 's safety and/or compliance study procedure Participant human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) coinfection Female participant pregnant , plan become pregnant , breastfeed , partner female participant pregnant breastfeed Participant hypersensitivity tartrazine Participant participate clinical trial investigational drug within 90 day drug administration participate 2 drug study last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Pegylated-interferon-alfa-2a</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Copegus</keyword>
</DOC>